I will drive AVX420 forward in immune related cancer diseases

I will establish and run Studies&Me as CEO. A company that will put the patient in front of a clinical trial, in an one entry digital platform from recruitment to last visit, utilizing our online hospital with investigator capability and a patient care team to ensure that patients are getting the best experience. All said we’re getting closer to the patients real world, improving data quality, and personalizing the treatment development.

Medical and scientific responsible in an entrepreneurial venture with a highly experienced team in the start-up business, LEO innovation Lab. Our goal is to discover and uncover the unmet needs of those living with psoriasis and then to develop new services and solutions to enable them to live a better life. We passionately believe that today’s offerings need to be integrated, and that tomorrow’s most wanted services will include but are not limited to digital solutions. Our ambition is to innovate with speed and launch our first solution within 6 months.

EU5+ covers the following countries: Australia, Canada, France, Germany, Ireland, Italy, New Zealand, Spain, United Kingdom.Primary disease focus areas: Psoriasis, Actininc Keratoses (Solar Keratoses).Secondary disease focus areas: Eczema, Skin Infections, Acnes and Deep Vein Thrombosis.The work includes among other things strategic consulting at affiliate level, consolidated regional medical plans & development of the regional strategy.

Medical expert in actinic keratosis, non-melanoma skin cancer and the topical treatment modality ingenol mebutate gel (Picato(R)). Within these areas this also includes:- Globally strategic responsible for investigator initiated studies and observational studies,- Medical strategic lead for the region EU5+ including UK, Germany and France,- Development of publications, educational tools and communication of those,- Review of Global commercial materials, ensuring alignment with the LEO medical strategy, regulatory rules and the codes of EFPIA and ABPI,- Chair Global advisory boards and expert panels,- Continuous scientific dialogue with HCPs and the medical staff in the markets,- Supporting Public Affairs and Market Access with scientific input,- Due diligence of novel product ideas.

Dermatology, inflammatory skin diseases, non-melanoma skin cancer

Molecular biomedicine and gene therapy.

As Freelance Consultant in Team Training and Paramedics, I'm educating teams in collaboration using scientific validated tools in outdor adventure environments and furthermore educating in lifesaving frist aid.

Current work and major fields of interest:• Ph.D. research project ‘Electro gene transfection as therapy of psoriasis vulgaris’, part of the 6th EU frame-project ANGIOSKIN.• Protein biology targets, gene electrotransfer in vivo, transcriptomics and non-coding RNAs, psoriasis, breast cancer, cancer, bioinformatics and oncogenomics: expression analysis, gene ontology and novel genome drug targets.

‘Transcriptional profiling of high and low risk breast tumors – a comparative study’, Master of Science research project. Laboratory of Oncology, University of Copenhagen at Herlev Hospital, Denmark and Dr. S.E. Bates Laboratory, Cancer Therapeutics Branch, National Cancer Institute, National Institute of Health, United States of America.

Instructor in Paramedics, basic life trauma support, physical education.Next in command platoon.